Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pathophysiology of Cheyne–Stokes respiration: lowering pulmonary capillary wedge pressure as causal therapy
2010-018892-20Phase 2Completed
- Sponsor
- Heart and Diabetes Center North Rhine-Westphalia
- Start
- Mar 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of nitroglycerin and iloprost in Cheyne-Stokes respiration (CSR), central sleep apnea (CSA) and heart failure (HF), sponsored by Heart and Diabetes Center North Rhine-Westphalia. Primary endpoint: Change in Apnoea–Hypopnoea Index (AHI) during glyceryl trinitrate/iloprost infusion. Started Mar 2010; status: completed.
02
Drugs
nitroglyceriniloprost
03
Conditions
Cheyne-Stokes respiration (CSR)central sleep apnea (CSA)heart failure (HF)
Beyond the preview
Go deeper on 2010-018892-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018892-20.